micro-community-banner
 
  • Saved
Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention - Neurological Sciences

Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention - Neurological Sciences

Source : https://link.springer.com/article/10.1007/s10072-022-06251-0

Background Anti-CGRP monoclonal antibodies (CGRPmAbs) enlarged migraine prevention options. They work targetedly, safely, and efficiently in many patients. Inexplicably, a proportion of patients show scarce improvement. Objective To identify the...


Discussion: Non-responders seem to have different personality traits in comparison to responders, with a higher tendency toward depressed mood and difficulty to feel pleasure previously found in migraineurs vs. non-migraineurs: the more strict certain traits are, the more difficult to treat the migraine could be.

  • Saved
Investigation of CACNA1I Cav3.3 Dysfunction in Hemiplegic Migraine

Investigation of CACNA1I Cav3.3 Dysfunction in Hemiplegic Migraine

Source : https://www.frontiersin.org/articles/10.3389/fnmol.2022.892820/full

Familial hemiplegic migraine (FHM) is a severe neurogenetic disorder for which three causal genes, CACNA1A, SCN1A, and ATP1A2, have been implicated. However, more than 80% of referred diagnostic cases of...


Conclusion/Relevance: We observed numerous functional alterations across the channels with Cav3.3-Q1158H showing the greatest differences compared to WT channels, including reduced current density, right-shifted voltage dependence of activation and inactivation, and slower current kinetics. Interestingly, we also found significant differences in...

  • Saved
Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis - Advances in Therapy

Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis - Advances in Therapy

Source : https://link.springer.com/article/10.1007/s12325-022-02233-y

Introduction In evaluating therapies for migraine prevention, emphasis is placed on frequency and less attention is paid to duration or severity. Total pain burden (TPB) combines frequency, duration, and severity...


Conclusion: GMB reduced mean TPB in patients who had previously not benefited from two to four categories of migraine preventive medication.

  • Saved
First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention - Pain and Therapy

First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention - Pain and Therapy

Source : https://link.springer.com/article/10.1007/s40122-022-00417-6

Introduction Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), formerly also called baboon syndrome, is characterized by symmetrical erythematous rash with typical localization in the gluteal and intertriginous areas. A type...



Conclusion: SDRIFE as a rare dermatological side effect should be considered in the monitoring of skin lesions during migraine prophylaxis. In view of the high migraine prevalence, knowledge of this uncommon syndrome is important. It is crucial to recognize the relationship between the medication and the circumscribed exanthema occurring...

  • Saved
Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors - Journal of Neurology

Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors - Journal of Neurology

Source : https://link.springer.com/article/10.1007/s00415-022-11225-5

Background Headache is one of the most frequently reported symptoms in post-COVID patients. The clinical phenotype of COVID-19 headache combines phenotypic features of both tension-type headache (TTH) and migraine. We...


Conclusions: This study provides real-world evidence of the potential benefit of AMT in patients with post-COVID-19 headache, especially in patients with history of TTH and without concomitant nausea.